Leung Ella H, Alsoudi Amer F, Skrehot Henry Chang, Burkhead Daniel, Adcock Bradley, Behl India, Chin Yee David
Georgia Retina, Atlanta, GA, USA.
Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA.
J Vitreoretin Dis. 2025 Jan 8:24741264241309685. doi: 10.1177/24741264241309685.
To compare the effects of intravitreal (IVT) 0.7 mg dexamethasone implants on the intraocular pressure (IOP) in Black patients and White patients with diabetic macular edema (DME). A retrospective cohort study was performed of Black patients and White patients with DME who received dexamethasone implants with 12 or more months of follow-up. The study included 145 eyes (69 Black; 76 White) with a mean (±SD) of 3.6 ± 3.9 dexamethasone implants and 58 31 months of follow-up. Black patients had higher baseline rates of glaucoma (23% vs 8%; = .010) but similar rates of ocular hypertension after receiving IVT dexamethasone (20% vs 16%; = .52). By the last follow-up visit, the mean central subfield thickness had decreased from 387 129 µm to 314 104 µm ( < .001). IVT dexamethasone implants decreased macular thicknesses in patients with DME; however, there was no difference in the rate of ocular hypertension after IVT dexamethasone between Black patients and White patients.
比较玻璃体内（IVT）注射0.7毫克地塞米松植入物对患有糖尿病性黄斑水肿（DME）的黑人患者和白人患者眼压（IOP）的影响。对接受地塞米松植入物且随访12个月或更长时间的患有DME的黑人和白人患者进行了一项回顾性队列研究。该研究纳入了145只眼（69只黑人患者的眼睛；76只白人患者的眼睛），平均（±标准差）植入3.6±3.9个地塞米松植入物，随访时间为58至31个月。黑人患者青光眼的基线发病率较高（23%对8%；P = 0.010），但接受IVT地塞米松治疗后高眼压的发病率相似（20%对16%；P = 0.52）。到最后一次随访时，平均中心子野厚度从387±129微米降至314±104微米（P < 0.001）。IVT地塞米松植入物可降低DME患者的黄斑厚度；然而，黑人患者和白人患者在接受IVT地塞米松治疗后的高眼压发病率没有差异。
